Abstract
The aim of this pilot study was to assess whether enfuvirtide can be discontinued in patients on long-term viral suppression. Eight patients with multidrug-resistant virus were randomly assigned to stop and 10 subjects to continue enfuvirtide. At week 48, viral rebound occurred in five (62.5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
ADP-ribosyl Cyclase 1 / analysis
-
CD4 Lymphocyte Count
-
CD8-Positive T-Lymphocytes / immunology
-
Drug Resistance, Viral / immunology
-
Enfuvirtide
-
HIV / immunology
-
HIV Envelope Protein gp41 / immunology
-
HIV Envelope Protein gp41 / therapeutic use*
-
HIV Fusion Inhibitors / immunology
-
HIV Fusion Inhibitors / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Infections / immunology
-
HIV Infections / virology
-
Humans
-
Mutation
-
Peptide Fragments / immunology
-
Peptide Fragments / therapeutic use*
-
Pilot Projects
-
Prospective Studies
Substances
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
Peptide Fragments
-
Enfuvirtide
-
ADP-ribosyl Cyclase 1